Tumor Board Tuesday 2023: Gastrointestinal Cancers


Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.


Supported by educational grants from Astellas; Astrazeneca Pharmaceuticals; Exelixis; Gilead Sciences, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck Sharp & Dohme Corp; and Seagen.


Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

Johnathan Ebben, MD, PhD
Oncology Fellow
Division of Hematology, Oncology, and Palliative Care
University of Wisconsin-Madison
Madison, Wisconsin


#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time. You can join the conversation at https://twitter.com/TumorBoardTues

Tuesday, October 10, 2023Decision making for 3L & Beyond - Colon Cancer
AMA credit
Anwaar Saeed, MD
Associate Professor of Medicine
Chief, Gastrointestinal Medical Oncology Program
University of Pittsburgh Medical Center (UPMC)
Director, Gastrointestinal Disease Center
UPMC Hillman Cancer Center

Robin Park, MD
Hematology/Oncology Fellow
Moffitt Cancer Center
University of South Florida
Anwaar Saeed, MD
Advisory Board: AstraZeneca, Bristol Myers Squibb, Exelixis, Merck, Pfizer
Research: Actuate Therapeutics, AstraZeneca, Bristol Myers Squibb, Clovis, Dragonfly Therapeutics, Exelixis, Incyte Corporation, Innovent Biologics, KAHR Medical, Merck, Oxford Biotherapeutics

Robin Park, MD has no real or apparent conflicts to disclose.
Tuesday, September 26, 2023CLAUDIN 18.2 in Gastric – New and Emerging TX
AMA credit
Samuel Klempner, MD
GI Medical Oncology
Associate Professor, Harvard Medical School
Mass General Cancer Center

Darren Cowzer, MD, MSc, MBBCh
Advanced GI Oncology Fellow
Division of Gastrointestinal Oncology
Memorial Sloan Kettering Cancer Centre
Samuel Klempner, MD
Advisory Board: Amgen, Astellas, AstraZeneca, BMS, Merck, Novartis, Sanofi-Aventis, Servier
Consulting: Novartis

Darren Cowzer, MD has no real or apparent conflicts to disclose.
Tuesday, August 29, 2023Investigating CLAUDIN 18.2 in Pancreatic Cancer
AMA credit
Wungki Park, MD, MS
Assistant Attending, Gastrointestinal Oncology Service
Assistant Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center

Fergus Keane, MD
Advanced Fellow in Gastrointestinal Oncology
Memorial Sloan Kettering Cancer Center
New York
Wungki Park, MD
Advisory: EXACT Therapeutics AS
Consultant: Astellas, Curio Science, TEMPUS
Research: Merck, Miracogen
Speaker: American Physician Institute

Fergus Keane, MD has no real or apparent conflicts to disclose.
Tuesday, July 25, 2023Differentiate Midgut & Pancreatic NETs
AMA credit
Mark Lewis, MD
Gastrointestinal Oncology
Intermountain Health

Catherine O'Connor
Research Student
Memorial Sloan Kettering Cancer Center Undergraduate
Davidson College
Mark Lewis, MD
Consultant: Ipsen, TerSera

Catherine O'Connor has no real or apparent conflicts to disclose
Tuesday, May 2, 2023Hypermutation in pNET
AMA credit
Rachel Riechelmann, MD, PhD
Director of The Clinical Oncology Department
AC Camargo Cancer Center

Jéssica Zanotti, MD
Medical Oncology Fellow
AC Camargo Cancer Center
Rachel Riechelmann, MD, PhD
Consultant: AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme

Jéssica Zanotti, MD has no real or apparent conflicts to disclose
Tuesday, March 21, 2023EGFR with RAF/RAS testing
AMA credit
Shafia Rahman, MD
Department of Internal Medicine Division of Medical Oncology
The Ohio State University
Columbus, OH

Zachary Risch, MD
Medical Oncology Fellow
The Ohio State University
Columbus, OH
Shafia Rahman, MD has no real or apparent conflicts to disclose

Zachary Risch, MD has no real or apparent conflicts to disclose


Oncologists and other clinicians who treat patients with gastrointestinal (GI) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of colorectal, gastric, esophageal, and biliary tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GI cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.


This activity is designed to meet the needs of medical, surgical and radiation oncologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in treatment and management of patients with gastrointestinal cancers.


Upon completion of this educational activity, participants will be able to:


There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

If you wish to claim credit for your participation in TBT conversations from March 21, 2023 – Present you can do so here: www.integrityce.com/TBTeval23




Physician Continuing Education

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this live material for a maximum of 6.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

Johnathan Ebben, MD, PhD
Other (CEO): NanoRED

The Integrity Continuing Education, Inc. planners and managers and Tumor Board Tuesday patient planner do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.